Moleculin reports interim AML trial data showing higher remission rates

June 30, 2026 8:30 AM

Moleculin Biotech, Inc. (Nasdaq: MBRX) announced interim efficacy results from the first 45 patients enrolled in Part A of its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found